SCHEDULE: State Street Reports 4.6% Stake in Vir Biotechnology

State Street Corporation has disclosed a beneficial ownership of 4.6% in Vir Biotechnology Inc. as of September 30, 2026.

Summary

• State Street Corporation has filed a Schedule 13G, indicating its beneficial ownership of Vir Biotechnology Inc. common stock.
• As of September 30, 2026, State Street Corporation beneficially owns 7,822,781 shares, representing 4.6% of the class of securities.
• The filing specifies that State Street Corporation has sole voting power of 0 shares and shared voting power of 7,507,527 shares.
• For dispositive power, State Street Corporation has sole power of 0 shares and shared power of 7,822,781 shares.
• The filing is made under Rule 13d-1(b), classifying State Street Corporation as a holder of securities in the ordinary course of business, not for the purpose of influencing control.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting on existing beneficial ownership without significant new information or strategic shifts.

Positives

• State Street Corporation's continued investment indicates confidence in Vir Biotechnology's long-term prospects.
• The filing confirms a significant institutional holding, which can provide stability to the stock.

Negatives

• The filing does not provide new financial performance data or strategic updates for Vir Biotechnology.
• The ownership percentage is below the threshold that typically triggers active influence or control.

Risks

• Potential for future changes in State Street Corporation's holdings, which could impact share price.
• The filing does not address specific business risks of Vir Biotechnology, only ownership details.

Future Outlook

The filing itself does not contain forward-looking statements or guidance for Vir Biotechnology. It solely reports on the ownership status of State Street Corporation.

Management Comments

• State Street Corporation certifies that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

StockSavvy.ai notes that this filing is a routine disclosure for significant institutional investors. Vir Biotechnology operates in the dynamic biotechnology sector, where significant institutional backing is common.

Stakeholder Impact

• Shareholders: The filing confirms a substantial institutional investor, which may be viewed positively for stock stability.
• Management: The filing indicates no intent to influence or control the company's management by State Street Corporation.

Next Steps

• State Street Corporation will continue to report any material changes in its beneficial ownership of Vir Biotechnology.

Key Dates

Keywords

Vir Biotechnology, State Street Corporation, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Biotechnology